ArticleFrontiers in pharmacology2025
Transcriptomic and metabonomic profiling unveils the mechanism of Tartary buckwheat and kiwi co-fermentation products in hyperlipidemia treatment.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of gemilukast as a bifunctional molecule with lipid-lowering and anti-inflammatory activities.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tartary buckwheat ( Methods: TB was co-fermented with kiwi juice (TB-KW) through alcohol fermentation to improve flavonoid extraction and utilization. The flavonoid profile of TB-KW was analyzed through untargeted metabolomics. The anti-hyperlipidemic effects of TB-KW were assessed in zebrafish maintained on a high-fat diet through transcriptomics and metabolomics. Results: Untargeted metabolomic analysis showed that flavonoids originating from TB, including quercetin, luteolin, quercitrin, rutin, and kaempferide, were significantly enriched in TB-KW. The data further showed that TB-KW significantly reduced lipid accumulation in zebrafish. Metabolomic profiling revealed 24 core differential metabolites (DEMs), spanning glycerophospholipids, sphingolipids, glycerolipids, and fatty acyls. Transcriptome analysis showed that TB-KW significantly regulated genes such as Discussion: These genes are associated with cholesterol metabolism and pathways linked to fat digestion and absorption, and they show a particular capacity to increase HDL synthesis. This study suggests the potential of TB-KW in improving flavonoid bioavailability and in the prevention and treatment of hyperlipidemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.